ArticleBioorganic & medicinal chemistry letters2015

Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib.

Mohit P Mathew et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.